NASDAQ: PAVMPavmed Inc Stock
$10.27-0.18 (-1.72%)
Updated Feb 17, 2026
PAVM Price
$10.27
Fair Value Price
N/A
Market Cap
$10.16M
52 Week Low
$6.00
52 Week High
$28.44
P/E
1.37x
P/B
0.31x
P/S
320.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$29.00k
Earnings
$3.10M
Gross Margin
-520.7%
Operating Margin
10,751.72%
Profit Margin
-2,051.7%
Debt to Equity
0.38
Operating Cash Flow
-$4M
Beta
1.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PAVM Overview
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PAVM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
PAVM
Ranked#81 of 103
Ranked#81 of 103
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.38 | A | |
| $28.05 | A | |
| $25.34 | A |
Be the first to know about important PAVM news, forecast changes, insider trades & much more!
PAVM News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PAVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PAVM was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PAVM is good value based on its earnings relative to its share price (1.37x), compared to the US market average (44.07x)
P/E vs Market Valuation
PAVM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PAVM due diligence checks available for Premium users.
Valuation
PAVM fair value
Fair Value of PAVM stock based on Discounted Cash Flow (DCF)
Price
$10.27
Fair Value
-$2.27
Undervalued by
551.85%
PAVM was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PAVM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.37x
Industry
21.83x
Market
44.07x
PAVM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PAVM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PAVM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
3.65x
PAVM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PAVM's financial health
Profit margin
Revenue
$5.0k
Net Income
-$5.4M
Profit Margin
-126,560%
PAVM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PAVM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.1M
Liabilities
$12.3M
Debt to equity
0.38
PAVM's short-term liabilities ($10.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PAVM's short-term assets ($4.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PAVM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PAVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$896.0k
Investing
-$3.0k
Financing
-$2.0k
PAVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PAVM vs Medical Device Stocks
Pavmed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.